Phathom Pharmaceuticals, Inc.

NasdaqGS PHAT

Phathom Pharmaceuticals, Inc. Market Capitalization on January 14, 2025: USD 464.28 M

Phathom Pharmaceuticals, Inc. Market Capitalization is USD 464.28 M on January 14, 2025, a 1.99% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Phathom Pharmaceuticals, Inc. 52-week high Market Capitalization is USD 1.26 B on November 07, 2024, which is 172.46% above the current Market Capitalization.
Phathom Pharmaceuticals, Inc. 52-week low Market Capitalization is USD 376.44 M on February 13, 2024, which is -18.92% below the current Market Capitalization.
Phathom Pharmaceuticals, Inc. average Market Capitalization for the last 52 weeks is USD 707.12 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGS: PHAT

Phathom Pharmaceuticals, Inc.

CEO	Ms. Terrie J. Curran
IPO Date	Oct. 25, 2019
Location	United States
Headquarters	100 Campus Drive
Employees	452
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Key trends

Past 5 years